A&D Medical rolls out new monitoring devices
SAN JOSE, Calif. A&D Medical on Wednesday introduced three new wireless telehealth and wellness devices featuring ANT technology.
A&D Medical’s monitoring devices with ANT wireless technology are essential feedback components for wellness coaching and health tracking, the company stated. Suitable for Web-based employee health programs, disease management, prevention programs and consumer wellness solutions, A&D Medical’s ANT devices enable a richer, more data-driven experience for both program administrators and end users.
These three A&D Medical products are designed for use with both mHealth and eHealth applications. Using ANT technology, the new products include a tri-axial activity monitor, precision personal health scale and an automatic blood pressure monitor. Each of these products feature an ANT wireless radio with automatic data transmission for seamless health metrics tracking.
ANT is a proven protocol and silicon solution for ultra-low-power practical wireless networking applications. It is designed for ease of use, efficiency and scalability with an installed base of more than 11 million nodes to date.
Actavis gets FDA approval for generic Cozaar
MORRISTOWN, N.J. Actavis has received regulatory approval from the Food and Drug Administration for its high blood pressure drug.
The drug maker said its losartan potassium tablets, USP, will be available in 25-mg, 50-mg and 100-mg strengths. The drug is a generic version of Merck’s Cozaar.
Losartan potassium tablets, USP, had sales of approximately $940 million for the 12 months ended June 30, according to IMS Health.
Express Scripts looks to curb nonadherence among patients
ST. LOUIS Pharmacy benefit manager Express Scripts said it has created a way to accurately predict which patients were most at risk of not adhering to their medications.
The PBM announced Monday that it had created a computer model that could predict whether a patient would fail to take medications as prescribed up to a year in advance, allowing early intervention to improve adherence. The company said patent protection for the model is pending. According to Express Scripts’ 2009 Drug Trend Report, nonadherence results in $106 billion being wasted on increased medical costs every year.
“The problem of nonadherence isn’t new — it’s easy to walk through a hospital and identify people who would not be there if they had simply taken their medications,” Express Scripts chief medical officer Steven Miller said. “But our new predictive models allow us to do something that wasn’t possible before: better identify those patients before they run into trouble and tailor practical, patient-centric solutions that target the specific factors that put them at risk for nonadherence.”